Press releases

All press releases Regulatory

Regulatory press release 2026-05-12

Bulletin from the annual general meeting of Xspray Pharma AB (publ) 12 May 2026

Regulatory press release 2026-04-30

New number of shares and votes in Xspray Pharma after new share issue April 2026

Regulatory press release 2026-04-28

Interim Report First Quarter 2026

Regulatory press release 2026-04-23

Xspray’s rights issue oversubscribed – over-allotment issue fully utilized

Press release 2026-04-14

FDA accepts trade name Nilopki® for Xspray’s drug candidate XS003 (nilotinib)

Regulatory press release 2026-04-09

Notice of annual general meeting of Xspray Pharma AB (publ)

Regulatory press release 2026-03-31

Xspray publishes disclosure document regarding rights issue

Press release 2026-03-26

Xspray receives additional subscription undertakings; rights issue now covered to 110% and over-allotment issue increased

Regulatory press release 2026-03-26

Xspray Pharma publishes its Annual Report 2025

Regulatory press release 2026-03-24

Xspray resolves on a rights issue of approximately SEK 83 million with an over-allotment issue

IR contact

Jacob Nyberg, IRO

+46 (0)70 767 08 83

info@xspray.com

Subscribe